34º Congresso Mineiro de Cardiologia
Acesse o site do congresso
1º Dia - 7/10/25
2º Dia - 7/11/25
3º Dia - 7/12/25

Aula CM 9: Metas do LDL – eficácia e segurança Voltar

Leonor de Oliveira Diniz

Simpósio Conjunto SMC e SBEM-MG (Cardiometabolismo) 2 - Neander de Souza Ferreira e Bárbara Campolina e Silva

Artigo Autor(es) Referência
Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention. Garcia-Gil Maria, Alves-Cabratosa Lia, Cunillera Oriol, Blanch Jordi, Martí-Lluch Ruth, Ponjoan Anna, Ribas-Aulinas Francesc, Tornabell-Noguera Èric, Zacarías-Pons Lluís, Domínguez-Armengol Gina, Guzmán Elizabeth, Ramos Rafel European journal of clinical investigation. 2024 Sep; 54(Sep):e14258. doi: 10.1111/eci.14258. pii: .
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. Sabatine Marc S, Wiviott Stephen D, Im KyungAh, Murphy Sabina A, Giugliano Robert P JAMA cardiology. 2018 Sep; 3(Sep):823-828. doi: 10.1001/jamacardio.2018.2258. pii: .
Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Khan Safi U, Khan Muhammad U, Virani Salim S, Khan Muhammad Shahzeb, Khan Muhammad Zia, Rashid Muhammad, Kalra Ankur, Alkhouli Mohamad, Blaha Michael J, Blumenthal Roger S, Michos Erin D European journal of preventive cardiology. 2022 Feb; 28(Feb):2001-2009. doi: 10.1093/eurjpc/zwaa093. pii: .
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney P M, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Lancet (London, England). 2005 Oct; 366(Oct):1267-78.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. , Baigent C, Blackwell L, Emberson J, Holland L E, Reith C, Bhala N, Peto R, Barnes E H, Keech A, Simes J, Collins R Lancet (London, England). 2010 Nov; 376(Nov):1670-81. doi: 10.1016/S0140-6736(10)61350-5. pii: .
Evidence-based goals in LDL-C reduction. Soran Handrean, Dent Ricardo, Durrington Paul Clinical research in cardiology : official journal of the German Cardiac Society. 2017 Apr; 106(Apr):237-248. doi: 10.1007/s00392-016-1069-7. pii: .
Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention. Jones Jeffrey E, Tang Kevin S, Barseghian Ailin, Wong Nathan D Journal of clinical medicine. 2023 Nov; 12(Nov):doi: 10.3390/jcm12237432. pii: 7432.
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Karagiannis Angelos D, Mehta Anurag, Dhindsa Devinder S, Virani Salim S, Orringer Carl E, Blumenthal Roger S, Stone Neil J, Sperling Laurence S European heart journal. 2021 Jun; 42(Jun):2154-2169. doi: 10.1093/eurheartj/ehaa1080. pii: .
How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Cybulska Barbara, Kłosiewicz-Latoszek Longina, Penson Peter E, Nabavi Seyed Mohammad, Lavie Carl J, Banach Maciej, Progress in cardiovascular diseases. 2021 ; 67():65-74. doi: 10.1016/j.pcad.2020.12.008. pii: S0033-0620(20)30210-3.
LDL cholesterol goals in high-risk patients: how low do we go and how do we get there? Besseling Joost, van Capelleveen Julian, Kastelein John J P, Hovingh G Kees Drugs. 2013 Mar; 73(Mar):293-301. doi: 10.1007/s40265-013-0028-0. pii: .
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Underberg James, Toth Peter P, Rodriguez Fatima Postgraduate medicine. 2022 Nov; 134(Nov):752-762. doi: 10.1080/00325481.2022.2117498. pii: .
LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y. Elgendy Islam Y, Elshazly Mohamed B Annals of internal medicine. 2021 Apr; 174(Apr):JC38. doi: 10.7326/ACPJ202104200-038. pii: .
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. Giugliano Robert P, Wiviott Stephen D, Blazing Michael A, De Ferrari Gaetano M, Park Jeong-Gun, Murphy Sabina A, White Jennifer A, Tershakovec Andrew M, Cannon Christopher P, Braunwald Eugene JAMA cardiology. 2017 May; 2(May):547-555. doi: 10.1001/jamacardio.2017.0083. pii: .
Low LDL-C: Is It all Good News? Hartz Jacob Current atherosclerosis reports. 2024 Dec; 26(Dec):673-681. doi: 10.1007/s11883-024-01238-y. pii: .
Safety and Effectiveness of High-Intensity Statins Versus Low/Moderate-Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL-C Goals: A Systematic Review and Meta-Analysis. Soleimani Hamidreza, Mousavi Asma, Shojaei Shayan, Tavakoli Kiarash, Salabat Dorsa, Farahani Rad Farid, Askari Mani K, Nelson John, Ruzieh Mohammed, Hosseini Kaveh Clinical cardiology. 2024 Aug; 47(Aug):e24334. doi: 10.1002/clc.24334. pii: e24334.
Nenhuma revista foi definida para este congresso.